Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvir.2015.11.059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor Absorbed Dose Predicts Survival and Local Tumor Control in Colorectal Liver Metastases Treated with 90Y Radioembolization.
Cardiovasc Intervent Radiol
September 2025
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: To evaluate predictors of outcomes in colorectal liver metastases (CLM) patients undergoing 90Y radioembolization (TARE), focusing on the impact of tumor absorbed dose.
Materials And Methods: Patients' characteristics and dosimetry assessments were analyzed in 231 patients undergoing 329 TARE sessions from 09/2009 to 07/2023. Response was assessed using RECIST1.
Spectrum of therapeutic options in hepatocellular carcinoma.
J Exerc Rehabil
August 2025
Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Hepatocellular carcinoma (HCC) is a prevalent cancer with high mortality rates globally. This review explores various HCC treatments, including surgical resection, liver transplantation, local ablation, and systemic therapies. With advancements in surgical techniques, local therapies, and immunotherapy, the treatment paradigm for HCC is rapidly evolving.
View Article and Find Full Text PDFStereotactic Body Radiation Therapy Facilitating Debulking Surgery in Metastatic VIPoma with Severe Diarrhea and Hypovolemic Shock.
Am J Case Rep
September 2025
Department of Hematology Oncology, University of Illinois, Chicago, IL, USA.
BACKGROUND Treatment of metastatic vasoactive intestinal peptide tumors (VIPoma) is challenging and requires a careful multidisciplinary approach to achieve optimal disease control. We present a case of metastatic VIPoma with recurring episodes of life-threatening diarrhea necessitating multiple intensive care unit (ICU) admissions. CASE REPORT A 54-year-old man presented with severe watery diarrhea and metabolic acidosis with MRI showing a necrotic pancreatic body mass, and multiple liver lesions.
View Article and Find Full Text PDFIs it a new era for intrahepatic cholangiocarcinoma?
Crit Rev Oncol Hematol
September 2025
Medical Oncology Unit, Department of Molecular and Clinical Sciences, AOU delle Marche, Polytechnic University of Marche, Ancona, Italy. Electronic address:
Intrahepatic cholangiocarcinoma (iCCA) is increasingly considered as a separate entity from other biliary tract cancers (BTCs), due to differences in aetiology, risk factors, pathobiology, anatomical and molecular biology characteristics. Surgery is the only curative option for the ∼ 30 % who are diagnosed with a resectable disease, while liver-directed therapies (LDTs - i.e.
View Article and Find Full Text PDFModern approach to hepatocellular carcinoma treatment.
World J Hepatol
August 2025
Interventional Radiology Unit, "F Miulli" Regional General Hospital, Acquaviva delle Fonti 70021, Italy.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, necessitating innovative treatment strategies. Surgical resection and liver transplantation continue to be the gold standards for early-stage HCC; however, advances in imaging and minimally invasive techniques have improved patient selection and outcomes. Additionally, the emergence of targeted therapies and immunotherapy has transformed the treatment landscape for advanced HCC.
View Article and Find Full Text PDF